Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
07/2005
07/07/2005WO2005060984A1 Method and apparatus for preventing and treating eyelid problems
07/07/2005WO2005060980A1 Drug for treating disease and drug for treating diabetes
07/07/2005WO2005060960A2 Use of histamine to treat bone disease
07/07/2005WO2005060938A1 Process for producing pellets for pharmaceutical compositions
07/07/2005WO2005060683A2 Small peptides for the treatment of alzheimer’s disease and other beta-amyloid protein fibrillogenesis disorders
07/07/2005WO2005060573A2 Pna-neamine conjugates and methods for producing and using the same
07/07/2005WO2005060541A2 Peptides and methods for inducing cellular resistance to infection
07/07/2005WO2005060479A2 Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same
07/07/2005WO2005060375A2 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like protein
07/07/2005WO2005060350A2 Diastereomeric peptides useful as inhibitors of membrane protein assembly
07/07/2005WO2005051483A3 Electrical devices and anti-scarring agents
07/07/2005WO2005044844A3 Protozoan strains of reduced virulence and use thereof
07/07/2005WO2005041960A3 Neuromuscular blocking agents and antagonists thereof
07/07/2005WO2005040192A3 Human cathelicidin antimicrobial peptides
07/07/2005WO2005039495A3 Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
07/07/2005WO2005038006A3 Chimeric metabotropic glutamate receptors and uses thereof
07/07/2005WO2005032461A3 Novel peptide with osteogenic activity
07/07/2005WO2005026724A3 Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a5 (slc22a5)
07/07/2005WO2005021741A3 Diagnostics and therapeutics for diseases associated with kallikrein 11 (klk11)
07/07/2005WO2005020970A3 Protease inhibitor compositions for prevention and treatment of skin conditions
07/07/2005WO2005016288A3 Methods and compositions for treatment of viral diseases
07/07/2005WO2005016266A3 Methods for treating cardiovascular disease using a soluble ctla4 molecule
07/07/2005WO2005016265A3 Method for promoting bone growth
07/07/2005WO2005014798A3 Novel compositions and methods for promoting, inhibiting, and detecting protein entry into cells
07/07/2005WO2005014639A3 Periodic antimicrobial peptides
07/07/2005WO2005014617A3 Cyclic peptide compositions and methods for treatment of sexual dysfunction
07/07/2005WO2005007086A3 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
07/07/2005WO2005003293A3 pRNA CHIMERA
07/07/2005WO2004110356A3 Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
07/07/2005WO2004108757A3 Antimicrobial polypeptides
07/07/2005WO2004103304A3 Treatment of t-cell mediated diseases
07/07/2005WO2004103149A3 Genes encoding single chain human leukocyte antigen e (hla-e) proteins to prevent natural killer cell-mediated cytotoxicity
07/07/2005WO2004100868A3 Method of treating transplant rejection
07/07/2005WO2004092340A3 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
07/07/2005WO2004085666A3 Secreted proteins
07/07/2005WO2004080425A3 Polypeptide compounds for inhibiting angiogenesis and tumor growth
07/07/2005WO2004072296A3 Compositions for modulating immune cell activity and methods for detection thereof
07/07/2005WO2004053078A3 METHODS FOR MODULATING IKKα ACTIVITY
07/07/2005WO2004052290A3 Compositions, splice variants and methods relating to breast specific genes and proteins
07/07/2005WO2004050007A3 Mammalian bt-42 proteins involved in the regulation of energy homeostasis
07/07/2005WO2004046167A3 Synthesis and self-assembly of abc triblock bola peptide
07/07/2005WO2004045554A3 Cytomodulating peptides for treating interstitial cystitis
07/07/2005WO2004035763A3 Antisense modulation of gfat expression
07/07/2005WO2004034957A3 Methods for treatment of helicobacter pylori-associated disorders
07/07/2005WO2004004779A8 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine
07/07/2005WO2003089583A3 Tissue specific genes and gene clusters
07/07/2005WO2003061571A3 Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
07/07/2005WO2003053360A3 Treatment of ebv and khsv infection and associated abnormal cellular proliferation
07/07/2005WO2002088303A3 Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
07/07/2005WO2002066609A3 23565, a novel human zinc carboxypeptidase family member and uses thereof
07/07/2005US20050149995 Using transgenic animal cells as bioreactor for propagation of connective tissue protein for use in treatment of collagen diseases
07/07/2005US20050149994 Rapidly maturing fluorescent proteins and methods for using the same
07/07/2005US20050149175 Intravascular devices and fibrosis-inducing agents
07/07/2005US20050149173 Intravascular devices and fibrosis-inducing agents
07/07/2005US20050149158 Medical implants and anti-scarring agents
07/07/2005US20050149157 Electrical devices and anti-scarring agents
07/07/2005US20050149080 Medical implants and anti-scarring agents
07/07/2005US20050148763 Peg-binding pth or peg-binding pth derivative
07/07/2005US20050148585 Treating chronic venous ulcers, arterial ulcers, chronic decubitus, acute wounds with a cGMP PDE5 inhibitor; improved blood supply to the wound region; sildenafil analog; 5-[2-ethoxy-5-(4-ethylpiperazin-1ylsulfonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3 d]pyrimidin-7-one
07/07/2005US20050148572 2-(2,4-difluorophenyl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-isobutyl-2,5-dioxopiperazin-1-yl]-N,N-dimethylethanamide; to suppress uterine contractions; cyclization of leucine analogs
07/07/2005US20050148564 Gonane ring substituted with hydroxy group and alkylamide derivatives used for achieving sustained systemic concentrations of therapeutic or prophylactic GABA(gamma-aminobutyric acid)analogs following administration to animals
07/07/2005US20050148561 Novel triterpene derivatives, preparation thereof and use thereof
07/07/2005US20050148542 Higher viscosity; reduced turbulence around tissues during eye surgery; preventing damage
07/07/2005US20050148531 Antisense agents; blocking agents (biotin); high throughput screening
07/07/2005US20050148527 Catalytic nucleic acids; ribozymes; translation inhibition; gene expression inhibition; for treating cardiovascular disease; for neovascularization induction in heart tissue
07/07/2005US20050148525 Nucleic acid markers
07/07/2005US20050148516 Sugar transferase gnt-v having angiogenic effect
07/07/2005US20050148515 Peptidomimetics; determining ability to bind growth hormone secretagogue; ghrelin agonists; appetite stimulation; dietetics
07/07/2005US20050148514 Method and composition for treatment of angiogenesis
07/07/2005US20050148513 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
07/07/2005US20050148512 Medical implants and fibrosis-inducing agents
07/07/2005US20050148511 Fibroblast growth factor (FGF); enhanced receptor subtype specificity and/or affinity; for treatment of skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes; mitogens
07/07/2005US20050148510 Protein with a hedgehog N-terminal domain covalently bound to a polypeptide with 10-30 hydrophobic amino acids, C 8-24 aliphatic, saturated or unsaturated hydrocarbon residues, or a hydrophobic thio group
07/07/2005US20050148509 Insulin-like growth factor; fusion proteins; chimera; apoptosis
07/07/2005US20050148508 For diagnosis and treatment of angiogenesis-related diseases; nerve growth factors
07/07/2005US20050148507 Monocyte chemoattractant proteins incubated in phosphate buffer; for treatment of coronary artery disease, peripheral arterial occlusive disease, cerebral and mesenterial arterial occlusive diseases
07/07/2005US20050148506 Novel method of modulating bone-related activity
07/07/2005US20050148505 Genes and agents to regulate follicular development, ovulation cycle and steriodogenesis
07/07/2005US20050148504 Cysteine protease inhibitor
07/07/2005US20050148503 Comprises erythropoietin as active ingredient; for treatment of anemia, trypanosomiasis, or malaria
07/07/2005US20050148501 Methods of inducing ovulation using a non-polypeptide camp level modulator
07/07/2005US20050148500 Proteinaceous factor isolatable from X61 cells has the ability to increase the dopamine content in neurons
07/07/2005US20050148499 immunological oral tolerance-inducing amount of an active ingredient beta 2-glycoprotein-1or derivatives
07/07/2005US20050148498 Metalloprotease inhibiting activity, in particular collagenase and gelatinase, treating humans or mammals suffering from a condition or disease related to excessive degeneration of support by a metalloprotease; treat inflammatory diseases: arthrosis, parodontosis or ulcers
07/07/2005US20050148497 Method for administering glp-1 molecules
07/07/2005US20050148496 Methotrexate resistant, a TNF- alpha antagonist, an interleukin-1 receptor antagonist and a steroid; drug screening;
07/07/2005US20050148495 Using XMP.629 ( a peptide containing NH2-lys-leu-phe-arg-(1-naphthyl)-ala)-gln-ala-lys(3-naphthyl)-ala)CONH2 or a pharmaceutically acceptable salt or derivative as antiacne agent
07/07/2005US20050148494 Methods and compositions for controlling appetite and modulating insulin sensitivity
07/07/2005US20050148076 Packaging cell lines for generation of high titers of recombinant AAV vectors
07/07/2005US20050148075 With binding specificity for target nucleotides containing one or GNN triplets; regulating gene expression
07/07/2005US20050148071 Production of tyrosine hydroxylase positive neurons
07/07/2005US20050148062 Transgenic microorganisms comprising apoptosis associated genes for use as tools in identifying modulators for prevention and treatment of cell proliferative disorders
07/07/2005US20050148058 Protein stabilization
07/07/2005US20050148047 Glycosyltransferase for use in enhancing glycospingolipid production in cells and treatment of brain disorders
07/07/2005US20050148030 Using computer generated models to design immunoglobulin specific ligands; immunosuppressants; rational drug design
07/07/2005US20050148028 Matrix membrane fusion protein with improved solubility in membrane-free and detergent-free aqueous environments for use in identifying modulators of membrane transport
07/07/2005US20050148018 Methods of identifying inverse agonists of the serotonin 2A receptor
07/07/2005US20050148017 Antisense oligonucleotides against tenascin for the treating of vitiligo
07/07/2005US20050148016 Membrane protein for use as tool in identifying modulators for prevention and treatment of cell proliferative disorders
07/07/2005US20050148014 Regulation of human P2Y1-like G protein-coupled receptor
1 ... 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 ... 3163